Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program.
about
Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancerAssessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slideRole of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer.Quality assurance in clinical trials--the role of pathology.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerAssessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany.Human epidermal growth factor receptor 2 status of breast cancer patients in Asia: Results from a large, multicountry study.Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics.
P2860
Q35064067-4C85A9BE-1981-4BE5-B612-AAE7BDD86FA5Q35078787-E022660A-DEF1-4B86-86F3-3E0159F5489EQ35929360-3B22D7D8-40AC-47FA-A2A6-27EEE6A0F05CQ38257642-A17F59A0-9AC2-4245-A9B0-1B1BFF95C263Q38596988-0EA31FA1-14ED-43FE-9A2E-9B4442884B96Q38612634-1C282EBE-8046-48E5-A3F9-12019CF461C5Q38648408-80508ED0-B1FD-44E5-B0E1-5CC8B91FEBCFQ39263199-64FDFBC1-88CD-435B-9588-F9E8E2D3528FQ39661792-80272EE1-15BB-43E1-A36F-EDFAB841C643Q42316809-C8FCD16A-D51D-4290-B337-601873A1CF65Q46188099-98C9E7E6-4B95-4432-88F0-B64A934CBC61
P2860
Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Assessing HER2 amplification i ...... In Situ Hybridization Program.
@ast
Assessing HER2 amplification i ...... In Situ Hybridization Program.
@en
type
label
Assessing HER2 amplification i ...... In Situ Hybridization Program.
@ast
Assessing HER2 amplification i ...... In Situ Hybridization Program.
@en
prefLabel
Assessing HER2 amplification i ...... In Situ Hybridization Program.
@ast
Assessing HER2 amplification i ...... In Situ Hybridization Program.
@en
P2093
P2860
P1476
Assessing HER2 amplification i ...... In Situ Hybridization Program.
@en
P2093
Adrienne L Morey
Brigid Waite
Gelareh Farshid
Glenda McCue
Glenn D Francis
Jane E Armes
Margaret C Cummings
Michael Bilous
Peter D Robbins
Peter H Button
P2860
P2888
P304
P356
10.1007/S10549-012-2093-6
P407
P577
2012-06-08T00:00:00Z